Monopar Therapeutics Inc. With a focus on oncology, Monopar is committed to building a pipeline of innovative drugs and drug combinations through the licensing and acquisition of late preclinical and clinical-stage oncology therapeutics. Their goal is to reduce risk and accelerate clinical development, leveraging their scientific and clinical expertise.

Located in San Francisco, CA, and Chicago, IL, Monopar's team is driven by their personal experiences and deep expertise in translating new treatments for advanced cancer. They identify drug candidates that can be developed in combination with approved cancer drugs to mitigate toxicity and improve antitumor efficacy. Monopar's research is motivated by the increasing need for individualized therapies that synergistically target cancer cells.

One of their key drug candidates, camsirubicin, is designed to retain the anticancer activity of doxorubicin while minimizing toxic effects on the heart, offering the potential for improved efficacy and better patient outcomes. As a company passionate about oncology, Monopar aims to meet the market demand for transformative therapies in the fight against cancer